Strategic Board Growth MyOme has recently expanded its leadership with new board appointees, signaling a growth-oriented governance stance. This presents an opportunity to engage on enterprise partnerships, high-level collaborations, and strategic investment discussions with executives and board members.

Expanded Access The Zenith powered by MyOme collaboration with Natera and the launch of a broader access initiative at ACMG 2026 position MyOme to target clinical partners and direct-to-consumer channels seeking scalable genome analysis and long-read methylation capabilities.

Proactive Health Network PHN rollout connects concierge, executive health, and longevity clinics, creating a ready-made sales channel for enterprise health programs, risk modeling services, and proactive health reports across partner networks.

Clinical Diagnostics Focus Recent ACMG demonstrations and rare disease diagnostic advancements highlight opportunities to sell to hospital systems, genetics clinics, and specialty centers seeking advanced genomic analysis, actionable reports, and PRS-enabled risk assessments.

Financial Readiness With mid-market revenue and solid funding, MyOme has the financial footing for larger pilots, multi-site deployments, and contracted service agreements with health systems, biomarker programs, or payer-backed initiatives.